This trial is testing the effects of a new drug, alpha-TEA, when given with the existing drug trastuzumab, for the treatment of HER2+ breast cancer that has stopped responding to other treatments and has spread to other parts of the body.
- Stage IV Breast Cancer
- HER2-positive Breast Cancer
- Metastatic Breast Cancer
- Refractory Breast Cancer
2 Primary · 3 Secondary · Reporting Duration: Up to 4 years
Side Effects for
1 Treatment Group
Treatment (alpha-TEA, trastuzumab)
1 of 1
24 Total Participants · 1 Treatment Group
Primary Treatment: Trastuzumab · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 16 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What level of security can be expected when utilizing Trastuzumab for treatment?
"The safety of Trastuzumab was assessed as a 1 on our company's rating system due to the limited clinical data available for Phase 1 trials." - Anonymous Online Contributor
How many participants are enrolled in this experiment?
"Correct. According to the clinicaltrials.gov listing, this medical study was first posted on April 8th 2020 and is currently accepting participants. The trial requires 24 individuals from a single center for enrollment." - Anonymous Online Contributor
Are there remaining vacancies for potential participants in this clinical trial?
"The information residing on clinicaltrials.gov substantiates that this medical study is presently taking applicants, with the original post being dated April 8th 2020 and a recent update occurring June 17 2022." - Anonymous Online Contributor
Which maladies is Trastuzumab most commonly employed to combat?
"Trastuzumab is often utilized for the treatment of brca1 gene-related ailments. In addition, it can prove effective in helping patients cope with infection, inflammatory [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) (IBC), and general breast issues." - Anonymous Online Contributor